Previous close | 1.5320 |
Open | 1.5200 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.5320 - 1.5320 |
52-week range | 1.5150 - 2.9150 |
Volume | |
Avg. volume | 7,380 |
Market cap | 7.487B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 12.77 |
EPS (TTM) | 0.1200 |
Earnings date | N/A |
Forward dividend & yield | 0.06 (3.83%) |
Ex-dividend date | 31 July 2023 |
1y target est | N/A |
The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximately US$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Pharma for a triple artemisinin combination drug (Artemether-Lumefantrine-Amodiaquine fixed-dose formulation) against malaria in Africa and Southeast Asia, to accelerate the development and commercialization of this new drug.
Photocure ASA (OSE: PHO) and its partner Asieris Pharmaceuticals (SSE (LON:SSE): 688176) announced on Wednesday that their multinational Phase III clinical trial for Cevira (APL-1702) has successfully met its primary endpoint. Cevira, a photodynamic drug-device combination product, is in development for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL).
On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue of RMB21.395 billion; the net profit attributable to shareholders of the listed company was RMB1.777 billion, with a period-on-period growth of 15.74%.